Financials in USD. Standardized financial statements.
A compact view of how RegeneRx Biopharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $76,761 | $76,761 | $76,761 | $76,762 | $69,667 | $56,652 | $93,308 | $60,612 | $0 | $29,484 |
| Revenue Growth? | 0.0% | 0.0% | -0.0% | +10.2% | +23.0% | -39.3% | +53.9% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $0 | $6,638 | $4,921 | $65.107 | $81.043 | $3,048 | $237.344 | $203.185 | $367.275 | $188.643 |
| Gross Profit? | $76,761 | $70,123 | $71,840 | $76,696 | $69,585 | $53,604 | $93,070 | $60,408 | -$367 | $29,295 |
| Gross Margin? | +100.0% | +91.4% | +93.6% | +99.9% | +99.9% | +94.6% | +99.7% | +99.7% | 0.0% | +99.4% |
| Operating Expenses? | $1.48M | $1.41M | $1.37M | $1.34M | $1.39M | $1.50M | $1.77M | $1.77M | $1.55M | $943,735 |
| Operating Income? | -$1.40M | -$1.33M | -$1.29M | -$1.26M | -$1.32M | -$1.45M | -$1.67M | -$1.71M | -$1.55M | -$914,000 |
| EBITDA? | -$1.40M | $56,000 | -$1.29M | -$1.25M | -$1.90M | $559,023 | $405,806 | -$5.09M | -$1.55M | -$565,000 |
| Income Before Tax | -$1.73M | -$1.60M | -$1.52M | -$1.40M | -$1.99M | $385,092 | $229,125 | -$5.27M | -$2.75M | -$671,000 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $98,605 | $0 | $0 | $0 | $0 |
| Net Income? | -$1.73M | -$1.60M | -$1.52M | -$1.40M | -$1.99M | $286,487 | $229,125 | -$5.27M | -$2.75M | -$671,000 |
| EPS? | $-1.00 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $0.00 | $0.00 | $-0.05 | $-0.03 | $-0.01 |
| Diluted EPS? | $-1.00 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $0.00 | $0.18 | $-0.05 | $-0.03 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality